MedPath

Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant

Phase 2
Completed
Conditions
Graft Versus Host Disease
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific
Registration Number
NCT00003894
Lead Sponsor
Roswell Park Cancer Institute
Brief Summary

RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone marrow cells as foreign and may help treat patients with graft-versus-host disease.

PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating patients who have chronic graft-versus-host disease following bone marrow transplantation.

Detailed Description

OBJECTIVES: I. Determine the efficacy of thalidomide in patients with steroid dependent or refractory chronic graft vs host disease following an allogeneic bone marrow transplant. II. Determine the toxicity of this regimen in these patients.

OUTLINE: This is a randomized study. Patients are stratified according to the type of bone marrow transplant received (allogeneic vs matched unrelated donor) and type of chronic graft vs host disease (steroid dependent vs steroid refractory). Patients receive either oral thalidomide or placebo 2-4 times a day for 6 months. The drug is then tapered until stopped. If disease recurs, the drug may be restarted for a second 6 month course. The maximum duration of treatment is 18 months. Patients continue on steroid therapy, which is tapered during study therapy. If no response is seen after 8 weeks, patients may cross over to the other alternate drug. Patients are followed weekly for 1 month, then every month for 1 year.

PROJECTED ACCRUAL: A total of 36 patients (18 per arm) will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (10)

Louisiana State University School of Medicine

🇺🇸

New Orleans, Louisiana, United States

Brooke Army Medical Center

🇺🇸

Fort Sam Houston, Texas, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

Cook Children's Medical Center - Fort Worth

🇺🇸

Fort Worth, Texas, United States

University of Texas - MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Cancer Center of the Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

Simmons Cancer Center - Dallas

🇺🇸

Dallas, Texas, United States

Arkansas Children's Hospital

🇺🇸

Little Rock, Arkansas, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath